Your browser is no longer supported. Please, upgrade your browser.
GTHX [NASD]
G1 Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.25 Insider Own1.20% Shs Outstand42.38M Perf Week-11.18%
Market Cap394.49M Forward P/E- EPS next Y-3.88 Insider Trans-7.27% Shs Float38.67M Perf Month-18.21%
Income-133.70M PEG- EPS next Q-1.03 Inst Own75.10% Short Float23.29% Perf Quarter-34.02%
Sales42.20M P/S9.35 EPS this Y19.80% Inst Trans-0.00% Short Ratio10.06 Perf Half Y-49.06%
Book/sh4.21 P/B2.13 EPS next Y-6.60% ROA-50.60% Target Price41.00 Perf Year-57.98%
Cash/sh4.83 P/C1.86 EPS next 5Y- ROE-65.70% 52W Range8.04 - 37.07 Perf YTD-12.05%
Dividend- P/FCF- EPS past 5Y-27.10% ROI-49.60% 52W High-74.21% Beta2.07
Dividend %- Quick Ratio8.60 Sales past 5Y144.10% Gross Margin96.10% 52W Low18.91% ATR0.69
Employees122 Current Ratio8.70 Sales Q/Q-81.60% Oper. Margin- RSI (14)44.11 Volatility8.59% 6.65%
OptionableYes Debt/Eq0.17 EPS Q/Q-226.20% Profit Margin- Rel Volume0.67 Prev Close8.98
ShortableYes LT Debt/Eq0.17 EarningsNov 03 BMO Payout- Avg Volume894.71K Price9.56
Recom2.00 SMA20-3.13% SMA50-14.94% SMA200-41.18% Volume514,514 Change6.46%
Nov-04-21Downgrade JP Morgan Neutral → Underweight $20 → $19
Oct-15-21Resumed BTIG Research Buy $51
Sep-30-21Downgrade JP Morgan Overweight → Neutral $24 → $20
Nov-17-20Downgrade Raymond James Strong Buy → Outperform
Jun-26-20Initiated ROTH Capital Buy $55
Jan-21-20Reiterated H.C. Wainwright Buy $72 → $82
Aug-08-19Upgrade JP Morgan Neutral → Overweight
Feb-07-19Initiated B. Riley FBR Buy $55
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Dec-20-18Initiated Raymond James Strong Buy
Nov-08-18Reiterated Needham Buy $76 → $74
Sep-10-18Resumed BTIG Research Buy $80
May-29-18Initiated H.C. Wainwright Buy $61
May-18-18Reiterated Needham Buy $42 → $60
Jan-05-22 05:06AM  
Jan-04-22 09:15AM  
Jan-03-22 05:30PM  
Dec-16-21 06:00AM  
Dec-01-21 06:20PM  
07:00AM  
Nov-29-21 07:00AM  
Nov-12-21 08:25AM  
Nov-10-21 11:40AM  
Nov-06-21 10:45AM  
Nov-03-21 04:01PM  
07:45AM  
06:30AM  
Nov-01-21 06:00PM  
Oct-27-21 03:03PM  
Oct-20-21 08:00AM  
Oct-07-21 08:00AM  
Oct-01-21 04:30PM  
07:45AM  
Sep-22-21 07:35AM  
Sep-15-21 06:45AM  
Sep-03-21 07:45AM  
07:30AM  
Aug-08-21 03:27AM  
Aug-05-21 10:00AM  
03:31AM  
Aug-04-21 05:15PM  
04:01PM  
08:00AM  
Aug-02-21 06:50AM  
Jul-28-21 03:04PM  
08:00AM  
Jul-19-21 09:20AM  
Jul-15-21 04:05PM  
Jul-06-21 04:23AM  
Jul-02-21 07:30PM  
Jun-18-21 09:00AM  
Jun-16-21 07:00AM  
Jun-14-21 07:00AM  
Jun-04-21 04:01PM  
09:02AM  
09:01AM  
May-21-21 03:34AM  
May-19-21 05:01PM  
May-17-21 07:00AM  
May-10-21 06:50AM  
May-07-21 04:01PM  
May-06-21 04:30AM  
May-05-21 06:20PM  
04:01PM  
02:45PM  
Apr-28-21 10:00AM  
07:00AM  
Apr-26-21 09:42AM  
Apr-07-21 07:00AM  
Apr-06-21 05:14AM  
Apr-02-21 04:05PM  
Apr-01-21 07:30AM  
Mar-25-21 06:50AM  
Mar-24-21 08:50AM  
04:00AM  
Mar-05-21 04:05PM  
Mar-03-21 07:30AM  
Mar-02-21 06:59AM  
Feb-25-21 12:00AM  
Feb-24-21 05:23PM  
04:01PM  
02:30PM  
Feb-17-21 08:00AM  
Feb-14-21 08:10AM  
04:07AM  
Feb-12-21 07:41PM  
Feb-04-21 11:55PM  
07:30AM  
Jan-26-21 03:22PM  
Jan-11-21 06:30AM  
Jan-05-21 07:00AM  
Jan-04-21 07:00AM  
Dec-31-20 11:57PM  
Dec-14-20 09:56AM  
Dec-09-20 05:00PM  
Nov-30-20 10:30AM  
Nov-29-20 12:30PM  
Nov-24-20 07:00AM  
Nov-18-20 07:00AM  
Nov-15-20 08:18AM  
Nov-11-20 07:01AM  
Nov-08-20 07:56AM  
Nov-05-20 08:39AM  
Nov-04-20 09:32PM  
04:31PM  
04:01PM  
02:30PM  
Oct-28-20 07:01AM  
Oct-15-20 07:00AM  
Sep-30-20 04:01PM  
Sep-14-20 07:00AM  
Sep-02-20 07:01AM  
Aug-17-20 06:00AM  
Aug-05-20 04:01PM  
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer, as well as Phase II clinical trials for the treatment of neoadjuvant breast cancer; lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer; and license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hanson James S.General CounselJan 05Sale10.611,44515,33425,555Jan 05 08:48 PM
Malik RajeshChief Medical OfficerJan 05Sale10.611,44515,33463,855Jan 05 08:24 PM
Moses Jennifer K.CFOJan 05Sale10.611,44515,33435,555Jan 05 08:25 PM
MURDOCK TERRY LChief Operating OfficerJan 05Sale10.611,44515,33421,555Jan 05 08:25 PM
Avagliano MarkChief Business OfficerJan 05Sale10.611,44515,33421,555Jan 05 08:24 PM
Bailey John E. (Jack) Jr.President and CEOJan 03Sale10.4134,125355,262233,208Jan 05 08:24 PM
Velleca Mark A.DirectorNov 09Option Exercise0.3940,00015,600101,000Nov 10 04:05 PM
Velleca Mark A.DirectorJul 15Option Exercise0.3910,0003,90071,000Jul 15 04:01 PM
Velleca Mark A.DirectorJul 15Sale18.4910,000184,89861,000Jul 15 04:01 PM
Velleca Mark A.DirectorJul 14Option Exercise0.3910,0003,90071,000Jul 15 04:01 PM
Velleca Mark A.DirectorJul 14Sale19.0810,000190,82461,000Jul 15 04:01 PM
Velleca Mark A.DirectorJul 13Option Exercise0.3910,0003,90071,000Jul 15 04:01 PM
Velleca Mark A.DirectorJul 13Sale19.4510,000194,53661,000Jul 15 04:01 PM
Velleca Mark A.DirectorJun 17Option Exercise0.3910,0003,90071,000Jun 17 04:05 PM
Velleca Mark A.DirectorJun 17Sale21.7710,000217,72861,000Jun 17 04:05 PM
Velleca Mark A.DirectorJun 16Option Exercise0.3910,0003,90071,000Jun 17 04:05 PM
Velleca Mark A.DirectorJun 16Sale21.7410,000217,38461,000Jun 17 04:05 PM
Velleca Mark A.DirectorJun 15Option Exercise0.3910,0003,90071,000Jun 17 04:05 PM
Velleca Mark A.DirectorJun 15Sale22.3910,000223,90961,000Jun 17 04:05 PM
Velleca Mark A.DirectorMay 25Option Exercise0.3920,0007,80061,000May 25 06:29 PM
Velleca Mark A.DirectorMay 13Option Exercise0.3910,0003,90051,000May 13 04:43 PM
Velleca Mark A.DirectorMay 13Sale20.5410,000205,41341,000May 13 04:43 PM
Velleca Mark A.DirectorMay 12Option Exercise0.3910,0003,90051,000May 13 04:43 PM
Velleca Mark A.DirectorMay 12Sale20.0710,000200,69141,000May 13 04:43 PM
Velleca Mark A.DirectorMay 11Option Exercise0.3910,0003,90051,000May 13 04:43 PM
Velleca Mark A.DirectorMay 11Sale19.1010,000190,99741,000May 13 04:43 PM
Malik RajeshChief Medical OfficerMay 10Option Exercise0.3010,0003,00053,300May 11 04:23 PM
Malik RajeshChief Medical OfficerApr 22Option Exercise0.3915,0005,85058,300Apr 23 04:39 PM
Malik RajeshChief Medical OfficerApr 22Sale22.0715,000331,10043,300Apr 23 04:39 PM
Velleca Mark A.DirectorApr 15Option Exercise0.3910,0003,90051,000Apr 15 05:53 PM
Velleca Mark A.DirectorApr 15Sale24.9610,000249,63141,000Apr 15 05:53 PM
Velleca Mark A.DirectorApr 14Option Exercise0.3910,0003,90051,000Apr 15 05:53 PM
Velleca Mark A.DirectorApr 14Sale24.5310,000245,27241,000Apr 15 05:53 PM
Velleca Mark A.DirectorApr 13Option Exercise0.3910,0003,90051,000Apr 15 05:53 PM
Velleca Mark A.DirectorApr 13Sale23.8910,000238,86541,000Apr 15 05:53 PM
Malik RajeshChief Medical OfficerMar 23Option Exercise0.3915,0005,85058,300Mar 24 04:47 PM
Malik RajeshChief Medical OfficerMar 23Sale21.9415,000329,06043,300Mar 24 04:47 PM
Moses Jennifer K.CFOMar 03Option Exercise3.723,00011,16025,000Mar 04 04:54 PM
Malik RajeshChief Medical OfficerMar 02Option Exercise1.5515,00023,21958,300Mar 04 05:10 PM
Malik RajeshChief Medical OfficerMar 02Sale22.9515,000344,19243,300Mar 04 05:10 PM
Velleca Mark A.DirectorFeb 18Option Exercise3.7210,00037,20051,000Feb 18 05:49 PM
Velleca Mark A.DirectorFeb 18Sale26.0210,000260,15241,000Feb 18 05:49 PM
Velleca Mark A.DirectorFeb 17Option Exercise3.7210,00037,20051,000Feb 18 05:49 PM
Velleca Mark A.DirectorFeb 17Sale27.6410,000276,43341,000Feb 18 05:49 PM
Velleca Mark A.DirectorFeb 16Option Exercise3.7211,04041,06952,040Feb 18 05:49 PM
Velleca Mark A.DirectorFeb 16Sale35.2011,040388,65341,000Feb 18 05:49 PM
Malik RajeshChief Medical OfficerJan 27Option Exercise0.393,1001,20943,300Jan 29 04:07 PM